Intellectual Property Magazine
Gilead requests Covid-19 'vaccine' waiver
Ben Wodecki
Pharma giant Gilead has asked the US Food and Drug Administration to rescind an orphan drug designation for its antiviral
drug Remdesivir, for treatment of the Covid-19 virus.